TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CSL ( (AU:CSL) ) has issued an announcement.
CSL Limited has announced an update on its ongoing on-market buy-back program, revealing that a total of 2,139,429 ordinary fully paid securities have been bought back to date, with an additional 46,154 securities purchased on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and enhance shareholder value, reflecting a positive outlook on the company’s financial health and market positioning.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$225.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and manufacturing of innovative medicines and vaccines. The company is known for its contributions to the healthcare sector, particularly in the areas of immunology, hematology, and influenza vaccines.
Average Trading Volume: 1,320,912
Technical Sentiment Signal: Sell
Current Market Cap: A$87.54B
Find detailed analytics on CSL stock on TipRanks’ Stock Analysis page.